Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965536 | 0.79 | HRH3 (0.46) | POLBALDH1A1PKMHRH3 | |
| SCHEMBL17552087 | 0.78 | POLB (0.57) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL1483544 | 0.77 | LMNA (0.40) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL967849 | 0.77 | HRH3 (0.48) | POLBHRH3 | |
| SCHEMBL25045298 | 0.77 | POLB (0.55) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL17393683 | 0.74 | KDM4E (0.43) | POLBSMN1; SMN2HSD17B10SIGMAR1KDM1A | |
| SCHEMBL1481713 | 0.73 | POLB (0.61) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL2905479 | 0.73 | POLB (1.00) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL313814 | 0.73 | POLB (0.61) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 | |
| SCHEMBL1704847 | 0.73 | POLB (1.00) | POLBSMN1; SMN2CXCR4HSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1599482-A4 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LTD (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
| EP-1599482-A1 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | Teijin Pharma Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076458-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LIMITED (JP) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | POLB 2145/4885SMN1; SMN2 3512/4885CXCR4 3004/4885 |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | MAP3K1, MAP3K5, MAP3K15 | POLB 1321/4885SMN1; SMN2 3775/4885CXCR4 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.